New Analysis Demonstrates Impaired Work Productivity and Increased Unemployment Rates in Adults with X-linked Hypophosphataemia (XLH)

Contributed by: Business Wire

Tags

Research

Professional Services

Pharmaceutical

Medical Devices

Infectious Diseases

Genetics

Health Technology

Science

Biotechnology

Human Resources

Other Science

Health

Disease

More Like This

Kyowa Kirin Presents Real-World Evidence Demonstrating Clinically Meaningful Impact of Burosumab Treatment in Adults with X-linked Hypophosphatemia

NICE Enables Access to First Treatment That Targets the Underlying Pathophysiology of Rare Disease X-Linked Hypophosphataemia (XLH) in Adults1

Kyowa Kirin Responds to NICE’s Publication of Appraisal Consultation Document for CRYSVITA® (Burosumab), for Treatment of Rare Disease X-Linked Hypophosphataemia (XLH) in Adults1

Pulmonary Hypertension Awareness Month: Two European Studies Highlight the Urgency of Patients and Experts to Improve the Diagnosis and Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease

PR Newswire associated0

Orphalan becomes the first European company to enter in China's Wilson Disease market

PR Newswire associated0

New insights highlight unmet needs for people living with Lennox-Gastaut syndrome and significant burden of the disease

PR Newswire associated0

Pierre Fabre Laboratories, committed to combating rare pediatric diseases via innovative therapies

European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14